Exhibit 99.1
Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics
September 5, 2023
PITTSBURGH(BUSINESS
WIRE)Carmell Corporation (Nasdaq: CTCX) (Carmell), a regenerative care company, today announced the completion of post-merger integration with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company
(Axolotl).
As part of the post-merger planning process, Carmell announced the following changes effective September 1, 2023:
|
|
|
Rajiv Shukla, Executive Chairman of Carmell to serve as Chairman & CEO of Carmell.
|
|
|
|
Randy Hubbell to step down as CEO and serve as Advisor to the Chairman & CEO in addition to Josh
Sandberg, former CEO of Axolotl who is serving in a similar role. |
|
|
|
Changes to Carmells Board of Directors underway with three board members to step down and candidates with a
background in aesthetics being recruited. |
|
|
|
Milestone payment of $8 million to Axolotl Biologix rescheduled to Aug 31, 2024. |
|
|
|
Projected post-merger savings anticipated to be nearly $3 million per annum, including from the termination
of certain executives serving as part-time consultants and full-time employees in non-core areas or overlapping business functions. |
|
|
|
Focus on programs in aesthetics that have shorter paths to commercialization, specifically in skin rejuvenation
and dental bone healing. |
On behalf of Carmell Corp., I would like to thank Randy for his many years of service to the Team. I
look forward to working with him as an advisor on commercial strategy, said Mr. Shukla.
Mr. Hubbell said, I am proud of what we
accomplished at Carmell over the years and look forward to continuing to work with Carmell as an advisor.
About Carmell
Carmell is a commercial stage regenerative care company with a focus on using human biomaterials for aesthetics (skin and dental) and skin healing. Their
commercial product is human amnion allograft that can be used for the healing of diabetic foot ulcers, venous ulcers, recovery from MOHS surgery, conjunctival and corneal healing, and dental, endodontic, oral maxillofacial, and periodontal
regenerative procedures. Carmells R&D pipeline includes cosmetic and dental products under development. For more information, visit www.carmellrx.com
Forward-Looking Statements
This press release contains
forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: may, will, could,
would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential,
continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking
statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in
this press release include, but are not